

Antineoplastic Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/A0F3553DF47MEN.html>

Date: May 2018

Pages: 146

Price: US\$ 3,480.00 (Single User License)

ID: A0F3553DF47MEN

Abstracts

Report Summary

Antineoplastic Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antineoplastic Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Antineoplastic Drugs 2013-2017, and development forecast 2018-2023

Main market players of Antineoplastic Drugs in EMEA, with company and product introduction, position in the Antineoplastic Drugs market

Market status and development trend of Antineoplastic Drugs by types and applications

Cost and profit status of Antineoplastic Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA Antineoplastic Drugs market as:

EMEA Antineoplastic Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Antineoplastic Drugs Market: Product Type Segment Analysis (Consumption

Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Chemotherapeutic Agents
Biological/Immunotherapeutic Agents
Personalized Medicine

EMEA Antineoplastic Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals
Clinics
Cancer Rehabilitation Centers
Ambulatory Surgical Centers

EMEA Antineoplastic Drugs Market: Players Segment Analysis (Company and Product introduction, Antineoplastic Drugs Sales Volume, Revenue, Price and Gross Margin):

Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Baxter Healthcare
Boehringer Ingelheim
Aspen Global
Bayer AG
Teva pharmaceutical Industries
Johnson & Johnson
Merc & Co.
Pfizer
Accord Healthcare
Genentech
Lundbeck
AbbVie

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF ANTINEOPLASTIC DRUGS

- 1.1 Definition of Antineoplastic Drugs in This Report
- 1.2 Commercial Types of Antineoplastic Drugs
 - 1.2.1 Chemotherapeutic Agents
 - 1.2.2 Biological/Immunotherapeutic Agents
 - 1.2.3 Personalized Medicine
- 1.3 Downstream Application of Antineoplastic Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Cancer Rehabilitation Centers
 - 1.3.4 Ambulatory Surgical Centers
- 1.4 Development History of Antineoplastic Drugs
- 1.5 Market Status and Trend of Antineoplastic Drugs 2013-2023
 - 1.5.1 Asia Pacific Antineoplastic Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Antineoplastic Drugs Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Antineoplastic Drugs in Asia Pacific 2013-2017
- 2.2 Consumption Market of Antineoplastic Drugs in Asia Pacific by Regions
 - 2.2.1 Consumption Volume of Antineoplastic Drugs in Asia Pacific by Regions
 - 2.2.2 Revenue of Antineoplastic Drugs in Asia Pacific by Regions
- 2.3 Market Analysis of Antineoplastic Drugs in Asia Pacific by Regions
 - 2.3.1 Market Analysis of Antineoplastic Drugs in China 2013-2017
 - 2.3.2 Market Analysis of Antineoplastic Drugs in Japan 2013-2017
 - 2.3.3 Market Analysis of Antineoplastic Drugs in Korea 2013-2017
 - 2.3.4 Market Analysis of Antineoplastic Drugs in India 2013-2017
 - 2.3.5 Market Analysis of Antineoplastic Drugs in Southeast Asia 2013-2017
 - 2.3.6 Market Analysis of Antineoplastic Drugs in Australia 2013-2017
- 2.4 Market Development Forecast of Antineoplastic Drugs in Asia Pacific 2018-2023
 - 2.4.1 Market Development Forecast of Antineoplastic Drugs in Asia Pacific 2018-2023
 - 2.4.2 Market Development Forecast of Antineoplastic Drugs by Regions 2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole Asia Pacific Market Status by Types

- 3.1.1 Consumption Volume of Antineoplastic Drugs in Asia Pacific by Types
- 3.1.2 Revenue of Antineoplastic Drugs in Asia Pacific by Types
- 3.2 Asia Pacific Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in China
 - 3.2.2 Market Status by Types in Japan
 - 3.2.3 Market Status by Types in Korea
 - 3.2.4 Market Status by Types in India
 - 3.2.5 Market Status by Types in Southeast Asia
 - 3.2.6 Market Status by Types in Australia
- 3.3 Market Forecast of Antineoplastic Drugs in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Antineoplastic Drugs in Asia Pacific by Downstream Industry
- 4.2 Demand Volume of Antineoplastic Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Antineoplastic Drugs by Downstream Industry in China
 - 4.2.2 Demand Volume of Antineoplastic Drugs by Downstream Industry in Japan
 - 4.2.3 Demand Volume of Antineoplastic Drugs by Downstream Industry in Korea
 - 4.2.4 Demand Volume of Antineoplastic Drugs by Downstream Industry in India
 - 4.2.5 Demand Volume of Antineoplastic Drugs by Downstream Industry in Southeast Asia
 - 4.2.6 Demand Volume of Antineoplastic Drugs by Downstream Industry in Australia
- 4.3 Market Forecast of Antineoplastic Drugs in Asia Pacific by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTINEOPLASTIC DRUGS

- 5.1 Asia Pacific Economy Situation and Trend Overview
- 5.2 Antineoplastic Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 ANTINEOPLASTIC DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

- 6.1 Sales Volume of Antineoplastic Drugs in Asia Pacific by Major Players
- 6.2 Revenue of Antineoplastic Drugs in Asia Pacific by Major Players
- 6.3 Basic Information of Antineoplastic Drugs by Major Players
 - 6.3.1 Headquarters Location and Established Time of Antineoplastic Drugs Major

Players

6.3.2 Employees and Revenue Level of Antineoplastic Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 ANTINEOPLASTIC DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Hoffmann-La Roche

7.1.1 Company profile

7.1.2 Representative Antineoplastic Drugs Product

7.1.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Hoffmann-La Roche

7.2 Amgen

7.2.1 Company profile

7.2.2 Representative Antineoplastic Drugs Product

7.2.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Amgen

7.3 Bristol-Myers Squibb

7.3.1 Company profile

7.3.2 Representative Antineoplastic Drugs Product

7.3.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb

7.4 Baxter Healthcare

7.4.1 Company profile

7.4.2 Representative Antineoplastic Drugs Product

7.4.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Baxter Healthcare

7.5 Boehringer Ingelheim

7.5.1 Company profile

7.5.2 Representative Antineoplastic Drugs Product

7.5.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim

7.6 Aspen Global

7.6.1 Company profile

7.6.2 Representative Antineoplastic Drugs Product

7.6.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Aspen Global

7.7 Bayer AG

- 7.7.1 Company profile
- 7.7.2 Representative Antineoplastic Drugs Product
- 7.7.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
- 7.8 Teva pharmaceutical Industries
 - 7.8.1 Company profile
 - 7.8.2 Representative Antineoplastic Drugs Product
 - 7.8.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Teva pharmaceutical Industries
- 7.9 Johnson & Johnson
 - 7.9.1 Company profile
 - 7.9.2 Representative Antineoplastic Drugs Product
 - 7.9.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.10 Merc & Co.
 - 7.10.1 Company profile
 - 7.10.2 Representative Antineoplastic Drugs Product
 - 7.10.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Merc & Co.
- 7.11 Pfize
 - 7.11.1 Company profile
 - 7.11.2 Representative Antineoplastic Drugs Product
 - 7.11.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Pfize
- 7.12 Accord Healthcare
 - 7.12.1 Company profile
 - 7.12.2 Representative Antineoplastic Drugs Product
 - 7.12.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Accord Healthcare
- 7.13 Genentech
 - 7.13.1 Company profile
 - 7.13.2 Representative Antineoplastic Drugs Product
 - 7.13.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Genentech
- 7.14 Lundbeck
 - 7.14.1 Company profile
 - 7.14.2 Representative Antineoplastic Drugs Product
 - 7.14.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Lundbeck
- 7.15 AbbVie
 - 7.15.1 Company profile
 - 7.15.2 Representative Antineoplastic Drugs Product
 - 7.15.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of AbbVie

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTINEOPLASTIC DRUGS

- 8.1 Industry Chain of Antineoplastic Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTINEOPLASTIC DRUGS

- 9.1 Cost Structure Analysis of Antineoplastic Drugs
- 9.2 Raw Materials Cost Analysis of Antineoplastic Drugs
- 9.3 Labor Cost Analysis of Antineoplastic Drugs
- 9.4 Manufacturing Expenses Analysis of Antineoplastic Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTINEOPLASTIC DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Antineoplastic Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/A0F3553DF47MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A0F3553DF47MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970